CLAIM CARD
Mechanistically, preclinical data from Wang 2017b demonstrate that rapamycin inhibits the secretory phenotype of senescent cells via an Nrf2-independent mechanism, with senescent fibroblasts showing decreased Nrf2 protein (~65%) and mRNA levels (~45%) relative to presenescent counterparts. Leontieva 2016 describes gerosuppression by pan-mTOR inhibitors, showing that cells treated for 4 days re-proliferated as effectively in drug-free medium, suggesting a reversible senomorphic effect. Leontieva 2011 further characterizes how rapamycin shifts cells from senescence to quiescence rather than eliminating them, a mechanism that may underlie the immunomodulatory profile observed in clinical studies.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025